EYPT
EyePoint Pharmaceuticals Inc.
$13.09
+$0.88(+7.21%)
68
Overall
60
Value
91
Tech
55
Quality
Market Cap
$844.36M
Volume
1.51M
52W Range
$3.91 - $14.91
Target Price
$33.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | ||
| Total Revenue | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | -- | -- | $8.3M | $500.0K | $3.7M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $34.4M | $36.9M | $33.1M | $46.0M | $43.3M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $71.7M | $92.2M | $112.0M | $121.1M | $189.1M | ||
| Research & Development | $17.4M | $28.5M | $49.6M | $64.7M | $132.9M | ||
| Research Expense | $17.4M | $28.5M | $49.6M | $64.7M | $132.9M | ||
| Selling, General & Administrative | $46.0M | $53.1M | $60.3M | $51.8M | $52.5M | ||
| Selling & Marketing Expenses | $25.3M | $27.5M | $25.5M | $11.7M | $131.0K | ||
| General & Administrative Expenses | $20.7M | $25.6M | $34.8M | $40.1M | $52.4M | ||
| Salaries & Wages | -- | -- | -- | $12.1M | $36.7M | ||
| Depreciation & Amortization | $189.0K | $311.0K | $2.0M | $500.0K | $1.5M | ||
| Depreciation & Amortization | $189.0K | $311.0K | $2.0M | $500.0K | $1.5M | ||
| Amortization | $2.6M | $2.7M | $2.0M | -- | -- | ||
| Other Operating Expenses | $-8.3M | $-10.6M | $-8.3M | $1.6M | $3.3M | ||
| OPERATING INCOME | |||||||
| Operating income | $-37.3M | $-55.3M | $-99.6M | $-75.1M | $-145.9M | ||
| EBITDA | $-18.1M | $-28.8M | $-96.6M | $-69.0M | $-129.2M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $7.3M | $5.5M | $3.2M | $1.2M | -- | ||
| Net Non-Operating Interest Income/Expense | $-7.3M | $-5.5M | $1.1M | $-5.7M | -- | ||
| Other Income/Expense | $847.0K | $-2.4M | $-22.3M | $-5.6M | $-15.1M | ||
| Other Special Charges | $-847.0K | $2.4M | $572.0K | $5.6M | $15.1M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | $-20.7M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $20.7M | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-21.6M | $-31.6M | $-99.1M | $-69.5M | $-130.8M | ||
| Pre-Tax Income | $-28.8M | $-37.1M | $-102.3M | $-70.7M | $-130.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $-2.8M | $-2.9M | $-5.9M | $83.0K | $90.0K | ||
| NET INCOME | |||||||
| Net Income | $-45.4M | $-58.4M | $-102.3M | $-70.8M | $-130.9M | ||
| Net Income (Continuing Operations) | $-45.4M | $-58.4M | $-102.3M | $-70.8M | $-130.9M | ||
| Net Income (Discontinued Operations) | $-45.4M | $-58.4M | $-102.3M | $-70.8M | $-130.9M | ||
| Net Income (Common Stockholders) | $-28.8M | $-37.1M | $-102.3M | $-64.9M | $-130.9M | ||
| Normalized Income | -- | $-40.0M | -- | -- | $-129.5M | ||
| TOTALS | |||||||
| Total Expenses | $71.7M | $92.2M | $120.3M | $121.6M | $189.1M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $12.8M | $28.8M | $37.3M | $38.9M | $56.3K | ||
| Average Shares Outstanding (Diluted) | $12.8M | $28.8M | $37.3M | $38.9M | $56.3K | ||
| Shares Outstanding | $28.7M | $34.0M | $34.3M | $49.8M | $68.7M | ||
| Basic EPS | $-3.54 | $-2.03 | $-2.74 | $-1.82 | $-2.32 | ||
| Basic EPS (Continuing Operations) | $-3.54 | $-2.03 | $-2.74 | $-1.82 | $-2.32 | ||
| Diluted EPS | $-3.54 | $-2.03 | $-2.74 | $-1.82 | $-2.32 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.74 | $-1.82 | $-2.32 | ||
| OTHER METRICS | |||||||
| Other Gand A | $20.7M | $25.6M | $34.8M | $40.1M | $52.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EYPT | $13.09 | +7.2% | 1.51M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get EyePoint Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW